Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib Lenalidomide Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the context of salvage autologous hematopoietic cell transplantation.
Brief description of study
The purpose of this research study is to test if there are any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant. In an autologous stem cell transplant, the stem cells in your body that produce blood are removed from the body and then returned after treatment with chemotherapy.
Clinical Study Identifier: s18-01982
ClinicalTrials.gov Identifier: NCT03556332
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
